长风药业(02652)：董事会批准有关股份购回授权议案

Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its board has reviewed and approved a proposal to grant general authority for the repurchase of its issued H shares listed on the Main Board of the Hong Kong Stock Exchange, which will be presented for consideration and approval at a special general meeting of shareholders to be held at an appropriate time [1] Group 1 - The board of Changfeng Pharmaceutical has approved a resolution regarding the repurchase of H shares [1] - The proposal will be submitted for shareholder approval at a special general meeting [1]